BiotechTube
Home/Pipeline/EGEN-2784

EGEN-2784

End-stage kidney disease (ESKD)

Phase 1/2/3Active

Key Facts

Indication
End-stage kidney disease (ESKD)
Phase
Phase 1/2/3
Status
Active
Company
eGenesis

About eGenesis

eGenesis is a clinical-stage biotech developing human-compatible organs from genetically engineered pigs to solve the critical shortage of donor organs. The company's platform utilizes multiplex CRISPR-based gene editing to inactivate endogenous retroviruses, knock out immunogenic antigens, and insert human protective genes. With an FDA-cleared IND for its lead kidney program (EGEN-2784) now in a Phase 1/2/3 trial and a second IND for a liver program (EGEN-5784), eGenesis is a leader in advancing xenotransplantation from concept to clinical reality. The company is privately held and backed by prominent life science investors.

View full company profile

Therapeutic Areas

Organ FailureNephrologyHepatology

Other End-stage kidney disease (ESKD) Drugs

DrugCompanyPhase
Holly™NephroditePre-clinical/Clinical Development